Braidwell
Latest statistics and disclosures from Braidwell's latest quarterly 13F-HR filing:
- Top 5 stock holdings are Guardant Health, Bridgebio Pharma, Novocure, CGON, Nuvasive, and represent 20.59% of Braidwell's stock portfolio.
- Added to shares of these 10 stocks: APLS (+$73M), EWTX (+$52M), Bicara Therapeutics (+$42M), MDGL (+$39M), SRPT (+$36M), DXCM (+$30M), BNTX (+$29M), PEN (+$29M), DAWN (+$26M), REPL (+$23M).
- Started 16 new stock positions in IMTX, HLVX, PODD, VERV, DXCM, ZURA, Oruka Therapeutics, EWTX, Amphastar Pharmaceuticals In, BSX. BNTX, JSPR, Bicara Therapeutics, FULC, MDGL, XNCR.
- Reduced shares in these 10 stocks: PCVX (-$58M), EXAS (-$58M), Sarepta Therapeutics Inc Note 1.250 9/1 (-$56M), APGE (-$44M), TMO (-$39M), ARGX (-$38M), INSP (-$30M), TMDX (-$29M), IMCR (-$27M), AKRO (-$25M).
- Sold out of its positions in AKRO, Conmed Corp Note 2.250 6/1, ETNB, IMCR, LBPH, OM, Sarepta Therapeutics Inc Note 1.250 9/1, TMO, TMDX, LIVN.
- Braidwell was a net buyer of stock by $149M.
- Braidwell has $3.5B in assets under management (AUM), dropping by 10.67%.
- Central Index Key (CIK): 0001920938
Tip: Access up to 7 years of quarterly data
Positions held by Braidwell consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Braidwell
Braidwell holds 81 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Guardant Health Note11/1 (Principal) | 6.1 | $216M | 268M | 0.81 |
|
|
| Bridgebio Pharma Note 2.500% 3/1 (Principal) | 4.1 | $146M | 141M | 1.03 |
|
|
| Novocure Note11/0 (Principal) | 3.8 | $133M | 141M | 0.95 |
|
|
| Cg Oncology (CGON) | 3.4 | $120M | -4% | 3.2M | 37.73 |
|
| Nuvasive Note 0.375% 3/1 (Principal) | 3.2 | $112M | 114M | 0.98 |
|
|
| Xenon Pharmaceuticals (XENE) | 3.0 | $107M | +5% | 2.7M | 39.37 |
|
| Neurocrine Biosciences (NBIX) | 3.0 | $106M | +20% | 918k | 115.22 |
|
| Neogenomics Note 0.250% 1/1 (Principal) | 2.7 | $97M | 116M | 0.83 |
|
|
| Apogee Therapeutics (APGE) | 2.7 | $97M | -31% | 1.6M | 58.74 |
|
| Apellis Pharmaceuticals (APLS) | 2.6 | $90M | +410% | 3.1M | 28.84 |
|
| Ironwood Pharmaceuticals Note 1.500% 6/1 (Principal) | 2.3 | $83M | +3% | 93M | 0.89 |
|
| Dexcom Note 0.375% 5/1 (Principal) | 2.3 | $82M | +12% | 93M | 0.89 |
|
| Align Technology (ALGN) | 2.2 | $79M | +13% | 312k | 254.32 |
|
| Guardant Health (GH) | 2.2 | $77M | +19% | 3.3M | 22.94 |
|
| Insulet Corp Note 0.375% 9/0 (Principal) | 2.2 | $76M | -6% | 64M | 1.20 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 2.1 | $75M | -7% | 1.5M | 48.73 |
|
| Viking Therapeutics (VKTX) | 2.1 | $73M | +4% | 1.2M | 63.31 |
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 2.1 | $72M | +40% | 2.9M | 24.99 |
|
| Penumbra (PEN) | 2.0 | $70M | +70% | 361k | 194.31 |
|
| Dexcom Note 0.250%11/1 (Principal) | 2.0 | $70M | 74M | 0.95 |
|
|
| Maravai Lifesciences Hldgs I Com Cl A (MRVI) | 2.0 | $69M | -7% | 8.4M | 8.31 |
|
| Day One Biopharmaceuticals I (DAWN) | 1.9 | $68M | +60% | 4.9M | 13.93 |
|
| Spyre Therapeutics Com New (SYRE) | 1.8 | $64M | -12% | 2.2M | 29.41 |
|
| Repligen Corporation (RGEN) | 1.7 | $59M | +22% | 397k | 148.82 |
|
| Irhythm Technologies (IRTC) | 1.6 | $58M | +48% | 783k | 74.24 |
|
| Travere Therapeutics Note 2.500% 9/1 (Principal) | 1.5 | $54M | 56M | 0.96 |
|
|
| Alphatec Hldgs Note 0.750% 8/0 (Principal) | 1.5 | $53M | 58M | 0.90 |
|
|
| Argenx Se Sponsored Adr (ARGX) | 1.5 | $52M | -42% | 97k | 542.08 |
|
| Edgewise Therapeutics (EWTX) | 1.5 | $52M | NEW | 2.0M | 26.69 |
|
| Inspire Med Sys (INSP) | 1.4 | $50M | -37% | 239k | 211.05 |
|
| Sarepta Therapeutics (SRPT) | 1.3 | $46M | +352% | 370k | 124.89 |
|
| Bridgebio Pharma Note 2.250% 2/0 (Principal) | 1.3 | $45M | -18% | 54M | 0.84 |
|
| Intuitive Surgical Com New (ISRG) | 1.3 | $45M | -9% | 91k | 491.27 |
|
| Avadel Pharmaceuticals Com Shs (AVDL) | 1.3 | $44M | +16% | 3.4M | 13.12 |
|
| Bicara Therapeutics | 1.2 | $42M | NEW | 1.7M | 25.47 |
|
| Keros Therapeutics (KROS) | 1.2 | $41M | -27% | 707k | 58.07 |
|
| Glaukos (GKOS) | 1.2 | $41M | -37% | 312k | 130.28 |
|
| Madrigal Pharmaceuticals (MDGL) | 1.1 | $39M | NEW | 184k | 212.22 |
|
| Vaxcyte (PCVX) | 1.0 | $34M | -63% | 298k | 114.27 |
|
| Replimune Group (REPL) | 1.0 | $34M | +203% | 3.1M | 10.96 |
|
| Arvinas Ord (ARVN) | 0.9 | $32M | +148% | 1.3M | 24.63 |
|
| Krystal Biotech (KRYS) | 0.9 | $31M | +57% | 169k | 182.03 |
|
| Orthopediatrics Corp. (KIDS) | 0.9 | $30M | 1.1M | 27.11 |
|
|
| Dex (DXCM) | 0.8 | $30M | NEW | 441k | 67.04 |
|
| Biontech Se Sponsored Ads (BNTX) | 0.8 | $29M | NEW | 248k | 118.77 |
|
| Paragon 28 (FNA) | 0.8 | $28M | 4.1M | 6.68 |
|
|
| Relay Therapeutics (RLAY) | 0.7 | $25M | +16% | 3.5M | 7.08 |
|
| Alphatec Hldgs Com New (ATEC) | 0.6 | $23M | +84% | 4.0M | 5.56 |
|
| Harrow Health (HROW) | 0.6 | $20M | +47% | 440k | 44.96 |
|
| Cullinan Oncology (CGEM) | 0.6 | $20M | +567% | 1.2M | 16.74 |
|
| Amphastar Pharmaceuticals In Note 2.000% 3/1 (Principal) | 0.6 | $20M | NEW | 18M | 1.06 |
|
| EXACT Sciences Corporation (EXAS) | 0.6 | $20M | -74% | 286k | 68.12 |
|
| Ocular Therapeutix (OCUL) | 0.6 | $20M | +36% | 2.2M | 8.70 |
|
| Immatics SHS (IMTX) | 0.5 | $19M | NEW | 1.6M | 11.41 |
|
| Ironwood Pharmaceuticals Com Cl A (IRWD) | 0.5 | $18M | 4.4M | 4.12 |
|
|
| Boston Scientific Corporation (BSX) | 0.4 | $16M | NEW | 189k | 83.80 |
|
| Dianthus Therapeutics (DNTH) | 0.4 | $14M | +34% | 494k | 27.38 |
|
| 4d Molecular Therapeutics In (FDMT) | 0.4 | $13M | +231% | 1.2M | 10.81 |
|
| Celcuity (CELC) | 0.4 | $13M | +71% | 884k | 14.91 |
|
| Oruka Therapeutics | 0.4 | $13M | NEW | 516k | 24.51 |
|
| Haemonetics Corp Mass Note3/0 (Principal) | 0.3 | $11M | 12M | 0.93 |
|
|
| Alector (ALEC) | 0.3 | $10M | -9% | 2.2M | 4.66 |
|
| Zura Bio Class A Ord Shs (ZURA) | 0.3 | $10M | NEW | 2.5M | 4.06 |
|
| Insulet Corporation (PODD) | 0.3 | $9.9M | NEW | 43k | 232.75 |
|
| Nevro (NVRO) | 0.3 | $9.5M | 1.7M | 5.59 |
|
|
| Castle Biosciences (CSTL) | 0.3 | $9.5M | -20% | 332k | 28.52 |
|
| Xencor (XNCR) | 0.3 | $9.4M | NEW | 466k | 20.11 |
|
| Jasper Therapeutics Com New (JSPR) | 0.3 | $9.1M | NEW | 483k | 18.81 |
|
| Bridgebio Pharma (BBIO) | 0.2 | $7.6M | -13% | 298k | 25.46 |
|
| Lexeo Therapeutics (LXEO) | 0.2 | $6.6M | -47% | 729k | 9.04 |
|
| Pulmonx Corp (LUNG) | 0.2 | $6.2M | 753k | 8.29 |
|
|
| The Beauty Health Company Com Cl A (SKIN) | 0.2 | $5.8M | -20% | 4.0M | 1.44 |
|
| Cutera Note 4.000% 6/0 (Principal) | 0.1 | $5.0M | 29M | 0.17 |
|
|
| Cutera Note 2.250% 6/0 (Principal) | 0.1 | $4.0M | 25M | 0.16 |
|
|
| Fulcrum Therapeutics (FULC) | 0.1 | $3.8M | NEW | 1.1M | 3.57 |
|
| Verve Therapeutics (VERV) | 0.1 | $3.0M | NEW | 624k | 4.84 |
|
| Iovance Biotherapeutics (IOVA) | 0.1 | $2.0M | -85% | 218k | 9.39 |
|
| Hillevax (HLVX) | 0.1 | $1.9M | NEW | 1.1M | 1.76 |
|
| Lexicon Pharmaceuticals Com New (LXRX) | 0.0 | $1.3M | -90% | 802k | 1.57 |
|
| Dbv Technologies S A Sponsored Adr (DBVT) | 0.0 | $1.1M | -33% | 1.6M | 0.70 |
|
| Elevation Oncology (ELEV) | 0.0 | $284k | -80% | 474k | 0.60 |
|
Past Filings by Braidwell
SEC 13F filings are viewable for Braidwell going back to 2022
- Braidwell 2024 Q3 filed Nov. 14, 2024
- Braidwell 2024 Q2 filed Aug. 14, 2024
- Braidwell 2024 Q1 filed May 15, 2024
- Braidwell 2023 Q4 filed Feb. 14, 2024
- Braidwell 2023 Q3 filed Nov. 14, 2023
- Braidwell 2023 Q2 filed Aug. 14, 2023
- Braidwell 2023 Q1 filed May 15, 2023
- Braidwell 2022 Q4 filed Feb. 14, 2023